Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

Tan YV, Waschek JA.

ASN Neuro. 2011 Oct 6;3(4). pii: e00065. doi: 10.1042/AN20110024. Review.

2.

VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair.

Waschek JA.

Br J Pharmacol. 2013 Jun;169(3):512-23. doi: 10.1111/bph.12181. Review.

3.

Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.

Gonzalez-Rey E, Varela N, Chorny A, Delgado M.

Curr Pharm Des. 2007;13(11):1113-39. Review.

PMID:
17430175
4.

Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis.

Abad C, Waschek JA.

Curr Pharm Des. 2011;17(10):1025-35. Review.

PMID:
21524252
5.

Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP.

Abad C, Gomariz RP, Waschek JA.

Curr Top Med Chem. 2006;6(2):151-63. Review.

PMID:
16454764
6.

[Neuroprotective role of PACAP, VIP, and PHI in the central nervous system].

Sokołowska P, Dejda A, Nowak JZ.

Postepy Hig Med Dosw (Online). 2004;58:416-27. Review. Polish.

7.
8.

PACAP, VIP and their receptors in the metazoa: insights about the origin and evolution of the ligand-receptor pair.

Cardoso JC, Vieira FA, Gomes AS, Power DM.

Peptides. 2007 Sep;28(9):1902-19. Epub 2007 Jul 31. Review.

PMID:
17826180
9.

Neuroprotective potential of three neuropeptides PACAP, VIP and PHI.

Dejda A, Sokołowska P, Nowak JZ.

Pharmacol Rep. 2005 May-Jun;57(3):307-20. Review.

10.

VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies.

Moody TW, Ito T, Osefo N, Jensen RT.

Curr Opin Endocrinol Diabetes Obes. 2011 Feb;18(1):61-7. doi: 10.1097/MED.0b013e328342568a. Review.

11.

Role of VIP and PACAP in islet function.

Winzell MS, Ahrén B.

Peptides. 2007 Sep;28(9):1805-13. Epub 2007 May 6. Review.

PMID:
17559974
12.

Cardioprotective role of the VIP signaling system.

Dvoráková MC.

Drug News Perspect. 2005 Jul-Aug;18(6):387-91. Review.

PMID:
16247516
13.
14.

Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.

Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H.

Pharmacol Rev. 2000 Jun;52(2):269-324. Review.

16.

Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP.

Laburthe M, Couvineau A.

Regul Pept. 2002 Oct 15;108(2-3):165-73. Review.

PMID:
12220741
17.
18.

Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery.

Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H.

Pharmacol Rev. 2009 Sep;61(3):283-357. doi: 10.1124/pr.109.001370. Review.

19.

PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways.

Zhou CJ, Shioda S, Yada T, Inagaki N, Pleasure SJ, Kikuyama S.

Curr Protein Pept Sci. 2002 Aug;3(4):423-39. Review.

PMID:
12370005
20.

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.

Ganea D, Rodriguez R, Delgado M.

Cell Mol Biol (Noisy-le-grand). 2003 Mar;49(2):127-42. Review.

PMID:
12887096

Supplemental Content

Support Center